NN344
Source NN344 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
NN344 (LysB29(Nε‑lithocholyl‑γ‑Glu) des‑B30 human insulin) is a long‑acting basal insulin analogue that incorporates a lithocholic‑acid moiety. The modification promotes self‑assembly into high‑molecular‑weight hexameric rods after subcutaneous injection, creating a depot that releases insulin slowly over more than 24 hours. It has been investigated in animal models and a small randomized human clamp study as a potential once‑daily basal insulin.
Mechanism of Action
The lithocholyl side chain of NN344 binds weakly to serum albumin and drives the formation of zinc‑stabilised hexamers that stack into elongated rods in the subcutaneous space. This depot slowly dissociates, providing a sustained release of insulin that retains affinity for the insulin receptor, thereby lowering blood glucose in a prolonged, flat manner.
What the Research Shows
Three peer‑reviewed studies describe NN344. A 2006 preclinical study in pigs showed a glucose‑lowering effect lasting >24 h, with a constant glucose infusion rate from 5 to 19 h and evidence of large self‑assembled complexes (>5000 kDa) and albumin binding. A 2007 double‑blind, randomized clamp trial in 27 men with type‑2 diabetes compared NN344 to insulin detemir and glargine; all three showed similar shape and duration of action, but NN344 and detemir exhibited significantly lower within‑subject variability. A 2020 SAXS analysis detailed the structural transitions of NN344 from mono‑/di‑hexamers in the vial to long hexameric rods after injection, and demonstrated that mixing with unmodified insulin can modulate rod length and release profile.
Reported Benefits
Evidence suggests NN344 provides a basal insulin effect lasting at least 24 h with a flat glucose‑infusion profile, comparable to insulin glargine and detemir. In the human clamp study, within‑subject variability was lower than glargine, indicating more predictable dosing. Albumin binding and depot formation may contribute to the prolonged action, potentially reducing injection frequency.
Limitations of the Evidence
Clinical data are limited to a single small human trial and animal studies; long‑term efficacy, safety, and hypoglycaemia risk have not been established. The study population was restricted to men with type‑2 diabetes, and no head‑to‑head comparisons with newer basal analogues were reported. Regulatory approval status is unknown, and broader real‑world performance remains untested.
Safety Considerations
The abstracts do not report specific adverse events, but the limited sample size means rare or delayed effects could be missed. Potential safety considerations include typical basal insulin risks such as hypoglycaemia and injection‑site reactions, as well as the theoretical impact of large subcutaneous depots on absorption. Monitoring glucose closely when initiating NN344 would be advisable.
How It Is Administered
NN344 is intended for subcutaneous injection, formulated with zinc and phenol to stabilise hexamers. In the vial or pen, it exists as mono‑/di‑hexamers; after injection, increased salt concentration promotes assembly into long hexameric rods that slowly dissociate to release active insulin.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowDreyer LS, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateKlein O, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleLowJonassen I, et al.2006-01-01T00:00:00.000000Z
Frequently Asked Questions
How does NN344 differ from insulin glargine?
Both are long‑acting basal insulins, but NN344 carries a lithocholic‑acid side chain that binds albumin and forms high‑molecular‑weight hexamer rods after injection, whereas glargine relies on pH‑dependent precipitation. In a clamp study, NN344 showed similar duration but lower within‑subject variability.
Is NN344 approved for clinical use?
The abstracts do not mention regulatory approval; NN344 is described as a candidate basal insulin under investigation. Its prescription status remains unknown.
What dosing frequency is expected for NN344?
Animal and human clamp data indicate a glucose‑lowering effect lasting more than 24 hours, suggesting that once‑daily dosing could be feasible, similar to other basal insulins.
Are there any unique side effects associated with the depot formation?
The published studies did not report specific depot‑related adverse events. However, as with any subcutaneously injected depot, monitoring for injection‑site reactions and hypoglycaemia is recommended.
Can NN344 be mixed with other insulins?
The 2020 structural study showed that mixing NN344 with unmodified insulin can modulate the length of hexameric rods and potentially adjust release characteristics, but clinical implications of such mixtures have not been evaluated.
What is NN344?
NN344 (LysB29(Nε‑lithocholyl‑γ‑Glu) des‑B30 human insulin) is a long‑acting basal insulin analogue that incorporates a lithocholic‑acid moiety. The modification promotes self‑assembly into high‑molecular‑weight hexameric rods after subcutaneous injection, creating a depot that releases insulin slowly over more than 24 hours. It has been investigated in animal models and a small randomized human clamp study as a potential once‑daily basal insulin.